Fibrocell Develops FCX-013 Investigational Gene Therapy for Treatment of Linear Scleroderma – Scleroderma News
Scleroderma News |
Fibrocell Develops FCX-013 Investigational Gene Therapy for Treatment of Linear Scleroderma
Scleroderma News Fibrocell Science of Exton, Pa., recently started a preclinical dose-ranging study for FCX-013, an investigational drug to treat linear scleroderma. The company expects to initiate a safety study and apply for Investigational New Drug (IND) status to … |
